Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | IL1RN | P18510 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8204697 | 0.89 | PIK3CB (0.51) | ALPLPIK3CBCA1CA2CA9 | |
| SCHEMBL15648607 | 0.86 | PIK3CB (0.54) | ALPLPIK3CBCA1CA2CA9 | |
| SCHEMBL13180233 | 0.84 | PIK3CB (0.43) | ALPLPIK3CBPIK3CGPIK3CANR1I2 | |
| SCHEMBL11894843 | 0.83 | HTR6 (0.51) | CA1CA2CA9HDAC3HDAC4 | |
| SCHEMBL35210090 | 0.81 | CA1 (0.46) | ALPLPIK3CBCA1CA2CA9 | |
| SCHEMBL1558834 | 0.81 | CA1 (0.46) | ALPLPIK3CBCA1CA2CA9 | |
| SCHEMBL1331630 | 0.81 | CA1 (0.64) | CA1CA2CA9NR1I2HDAC3 | |
| SCHEMBL462147 | 0.79 | PIK3CB (0.55) | ALPLPIK3CBPIK3CA | |
| SCHEMBL20995717 | 0.79 | CA9 (0.62) | CA1CA2CA9HDAC3HDAC4 | |
| SCHEMBL20523442 | 0.78 | PGR (0.47) | ALPLCA1CA2CA9HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947225-B2 | Phosphotidylinositol 3-kinase inhibitors | EMORY UNIVERSITY (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947225-B2 | Phosphotidylinositol 3-kinase inhibitors | EMORY UNIVERSITY (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190202826-A1 | Phosphotidylinositol 3-Kinase Inhibitors | UNIV EMORY (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190202826-A1 | Phosphotidylinositol 3-Kinase Inhibitors | UNIV EMORY (US) | 2019-07-04 | — | — | US | disclosed |
| EP-3454852-A1 | PHOSPHOTIDYLINOSITOL 3-KINASE INHIBITORS | Emory University (US) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017197151-A1 | PHOSPHOTIDYLINOSITOL 3-KINASE INHIBITORS | EMORY UNIVERSITY (US) | 2017-11-16 | — | — | WO | disclosed |
| US-9422298-B2 | Pyridopyrimidine derivatives and use thereof | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-23 | — | — | US | disclosed |
| US-9422298-B2 | Pyridopyrimidine derivatives and use thereof | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-23 | — | — | US | disclosed |
| US-9422298-B2 | Pyridopyrimidine derivatives and use thereof | CMG PHARMACEUTICAL CO., LTD. (KR) | 2016-08-23 | — | — | US | disclosed |
| US-9073924-B2 | Azaindazoles | GLAXOSMITHKLINE LLC (US) | 2015-07-07 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| US-7592342-B2 | Quinoxaline derivatives as PI3 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2009039140-A1 | PYRIDOPYRIMIDINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2008150827-A1 | NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | GLAXOSMITHKLINE LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008141065-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141065-A1 | QUINOXALINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293706-A1 | QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS | PIP5K1A, PIK3CB, PIK3CG | ALPL 3010/4885PIK3CB 2/4885PIK3CG 3/4885 |
| US-20190202826-A1 | Phosphotidylinositol 3-Kinase Inhibitors | PIK3CA, PIK3CB, PIK3CG | ALPL 3888/4885PIK3CB 2/4885PIK3CG 3/4885 |
| US-10947225-B2 | Phosphotidylinositol 3-kinase inhibitors | PIK3CA, PIK3CB, PIK3CG | ALPL 3888/4885PIK3CB 2/4885PIK3CG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.